Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.

Tendler S, Grozman V, Lewensohn R, Tsakonas G, Viktorsson K, De Petris L.

Lung Cancer. 2018 Jun;120:75-81. doi: 10.1016/j.lungcan.2018.03.026. Epub 2018 Mar 30.

PMID:
29748020
2.

Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.

Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Hååg P, Bomzon Z, Kirson ED, Weinberg U, Viktorsson K, Lewensohn R, Palti Y.

Radiat Oncol. 2017 Dec 29;12(1):206. doi: 10.1186/s13014-017-0941-6.

3.

Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment.

Eriksson M, Hååg P, Brzozowska B, Lipka M, Lisowska H, Lewensohn R, Wojcik A, Viktorsson K, Lundholm L.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):174-187. doi: 10.1016/j.ijrobp.2017.09.033. Epub 2017 Sep 22.

PMID:
29107335
4.

Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.

Efazat G, Novak M, Kaminskyy VO, De Petris L, Kanter L, Juntti T, Bergman P, Zhivotovsky B, Lewensohn R, Hååg P, Viktorsson K.

Oncotarget. 2016 Sep 13;7(37):60332-60347. doi: 10.18632/oncotarget.11219.

5.

Preclinical activity of melflufen (J1) in ovarian cancer.

Carlier C, Strese S, Viktorsson K, Velander E, Nygren P, Uustalu M, Juntti T, Lewensohn R, Larsson R, Spira J, De Vlieghere E, Ceelen WP, Gullbo J.

Oncotarget. 2016 Sep 13;7(37):59322-59335. doi: 10.18632/oncotarget.11163.

6.

Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells.

Zovko A, Novak M, Hååg P, Kovalerchick D, Holmlund T, Färnegårdh K, Ilan M, Carmeli S, Lewensohn R, Viktorsson K.

Oncotarget. 2016 Aug 2;7(31):50258-50276. doi: 10.18632/oncotarget.10361.

7.

91P: Validation of the 7th and upcoming 8th TNM staging system in small cell lung cancer.

Tendler S, Lewensohn R, Viktorsson K, de Petris L.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S96. doi: 10.1016/S1556-0864(16)30204-0. Epub 2016 Apr 15. No abstract available.

8.

Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.

Viktorsson K, Shah CH, Juntti T, Hååg P, Zielinska-Chomej K, Sierakowiak A, Holmsten K, Tu J, Spira J, Kanter L, Lewensohn R, Ullén A.

Mol Oncol. 2016 May;10(5):719-34. doi: 10.1016/j.molonc.2015.12.013. Epub 2016 Jan 2.

9.

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines.

Salim H, Zong D, Hååg P, Novak M, Mörk B, Lewensohn R, Lundholm L, Viktorsson K.

BMC Cancer. 2015 Sep 9;15:628. doi: 10.1186/s12885-015-1635-9.

10.

Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma.

Zovko A, Viktorsson K, Hååg P, Kovalerchick D, Färnegårdh K, Alimonti A, Ilan M, Carmeli S, Lewensohn R.

Mol Cancer Ther. 2014 Dec;13(12):2941-54. doi: 10.1158/1535-7163.MCT-14-0329. Epub 2014 Oct 15.

11.

Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma.

Shah CH, Viktorsson K, Kanter L, Sherif A, Asmundsson J, Rosenblatt R, Lewensohn R, Ullén A.

Urol Oncol. 2014 Nov;32(8):1215-24. doi: 10.1016/j.urolonc.2014.04.015. Epub 2014 May 28.

PMID:
24880461
12.

Systems biology approaches to develop innovative strategies for lung cancer therapy.

Viktorsson K, Lewensohn R, Zhivotovsky B.

Cell Death Dis. 2014 May 29;5:e1260. doi: 10.1038/cddis.2014.28. Review.

13.

Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.

Lundholm L, Hååg P, Juntti T, Lewensohn R, Viktorsson K.

Int J Radiat Biol. 2014 Aug;90(8):718-26. doi: 10.3109/09553002.2014.905725. Epub 2014 Jun 25.

PMID:
24646078
14.

Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer.

Zong D, Zielinska-Chomej K, Juntti T, Mörk B, Lewensohn R, Hååg P, Viktorsson K.

Cell Death Dis. 2014 Mar 13;5:e1111. doi: 10.1038/cddis.2014.56.

15.

miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.

Salim H, Arvanitis A, de Petris L, Kanter L, Hååg P, Zovko A, Özata DM, Lui WO, Lundholm L, Zhivotovsky B, Lewensohn R, Viktorsson K.

Genes Chromosomes Cancer. 2013 Oct;52(10):895-911. doi: 10.1002/gcc.22085. Epub 2013 Aug 9.

PMID:
23929716
16.

APS8, a polymeric alkylpyridinium salt blocks α7 nAChR and induces apoptosis in non-small cell lung carcinoma.

Zovko A, Viktorsson K, Lewensohn R, Kološa K, Filipič M, Xing H, Kem WR, Paleari L, Turk T.

Mar Drugs. 2013 Jul 16;11(7):2574-94. doi: 10.3390/md11072574.

17.

A role for Myh1 in DNA repair after treatment with strand-breaking and crosslinking chemotherapeutic agents.

Jansson K, Alao JP, Viktorsson K, Warringer J, Lewensohn R, Sunnerhagen P.

Environ Mol Mutagen. 2013 Jun;54(5):327-37. doi: 10.1002/em.21784. Epub 2013 May 16.

PMID:
23677513
18.

Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.

Patel C, Stenke L, Varma S, Lindberg ML, Björkholm M, Sjöberg J, Viktorsson K, Lewensohn R, Landgren O, Gottesman MM, Gillet JP.

Cancer. 2013 Aug 15;119(16):3076-83. doi: 10.1002/cncr.28098. Epub 2013 May 14.

19.

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N, Richardson P, Lewensohn R, Anderson KC.

Clin Cancer Res. 2013 Jun 1;19(11):3019-31. doi: 10.1158/1078-0432.CCR-12-3752. Epub 2013 Apr 12.

20.

Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.

Shah CH, Viktorsson K, Sherif A, Kanter L, Grybäck P, Lewensohn R, Sandström P, Nilsson S, Ullén A.

Anticancer Drugs. 2013 Jul;24(6):648-52. doi: 10.1097/CAD.0b013e328360c1c3.

PMID:
23542751
21.

Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.

Lundholm L, Hååg P, Zong D, Juntti T, Mörk B, Lewensohn R, Viktorsson K.

Cell Death Dis. 2013 Jan 31;4:e478. doi: 10.1038/cddis.2012.211.

22.

Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412.

Ståhl S, Kaminskyy VO, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, Moshfegh A, Lewensohn R, Viktorsson K, Zhivotovsky B.

Cell Death Dis. 2013 Jan 10;4:e454. doi: 10.1038/cddis.2012.188.

23.

miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence.

Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, Viktorsson K, Zhivotovsky B.

Br J Cancer. 2012 Oct 9;107(8):1361-73. doi: 10.1038/bjc.2012.382. Epub 2012 Aug 28.

24.

Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair.

Malewicz M, Kadkhodaei B, Kee N, Volakakis N, Hellman U, Viktorsson K, Leung CY, Chen B, Lewensohn R, van Gent DC, Chen DJ, Perlmann T.

Genes Dev. 2011 Oct 1;25(19):2031-40. doi: 10.1101/gad.16872411.

25.
26.

Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.

Ståhl S, Branca RM, Efazat G, Ruzzene M, Zhivotovsky B, Lewensohn R, Viktorsson K, Lehtiö J.

J Proteome Res. 2011 May 6;10(5):2566-78. doi: 10.1021/pr200037u. Epub 2011 Apr 11.

PMID:
21413766
27.

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.

Wickström M, Viktorsson K, Lundholm L, Aesoy R, Nygren H, Sooman L, Fryknäs M, Vogel LK, Lewensohn R, Larsson R, Gullbo J.

Biochem Pharmacol. 2010 May 1;79(9):1281-90. doi: 10.1016/j.bcp.2009.12.022. Epub 2010 Jan 11.

PMID:
20067771
28.

Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86.

Beskow C, Skikuniene J, Holgersson A, Nilsson B, Lewensohn R, Kanter L, Viktorsson K.

Br J Cancer. 2009 Sep 1;101(5):816-21. doi: 10.1038/sj.bjc.6605201. Epub 2009 Aug 11.

29.

Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.

Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L.

Exp Hematol. 2009 Jun;37(6):755-66. doi: 10.1016/j.exphem.2009.03.002.

PMID:
19463775
30.

Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells.

Ståhl S, Fung E, Adams C, Lengqvist J, Mörk B, Stenerlöw B, Lewensohn R, Lehtiö J, Zubarev R, Viktorsson K.

Mol Cell Proteomics. 2009 May;8(5):1117-29. doi: 10.1074/mcp.M800274-MCP200. Epub 2009 Jan 23.

31.

An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B.

Mol Cancer Res. 2008 Oct;6(10):1630-8. doi: 10.1158/1541-7786.MCR-07-2172.

32.

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.

Wickström M, Johnsen JI, Ponthan F, Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson K, Lewensohn R, Kogner P, Larsson R, Gullbo J.

Mol Cancer Ther. 2007 Sep;6(9):2409-17.

33.

The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death.

Polischouk AG, Holgersson A, Zong D, Stenerlöw B, Karlsson HL, Möller L, Viktorsson K, Lewensohn R.

Mol Cancer Ther. 2007 Aug;6(8):2303-9.

34.

Apoptotic signaling pathways in lung cancer.

Viktorsson K, Lewensohn R.

J Thorac Oncol. 2007 Mar;2(3):175-9. No abstract available.

35.

Two distinct steps of Bak regulation during apoptotic stress signaling: different roles of MEKK1 and JNK1.

Ihrlund LS, Hernlund E, Viktorsson K, Panaretakis T, Barna G, Sabapathy K, Linder S, Shoshan MC.

Exp Cell Res. 2006 May 15;312(9):1581-9. Epub 2006 Mar 9.

PMID:
16529740
36.

Apoptotic pathways and therapy resistance in human malignancies.

Viktorsson K, Lewensohn R, Zhivotovsky B.

Adv Cancer Res. 2005;94:143-96. Review.

PMID:
16096001
37.

The role of p53 in treatment responses of lung cancer.

Viktorsson K, De Petris L, Lewensohn R.

Biochem Biophys Res Commun. 2005 Jun 10;331(3):868-80. Review.

PMID:
15865943
38.

Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line.

Viktorsson K, Ekedahl J, Lindebro MC, Lewensohn R, Zhivotovsky B, Linder S, Shoshan MC.

Exp Cell Res. 2003 Oct 1;289(2):256-64.

PMID:
14499626
39.

Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis.

Mandic A, Viktorsson K, Strandberg L, Heiden T, Hansson J, Linder S, Shoshan MC.

Mol Cell Biol. 2002 May;22(9):3003-13.

40.

Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner.

Mandic A, Viktorsson K, Molin M, Akusjärvi G, Eguchi H, Hayashi SI, Toi M, Hansson J, Linder S, Shoshan MC.

Mol Cell Biol. 2001 Jun;21(11):3684-91.

41.

The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis.

Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC.

Melanoma Res. 2001 Feb;11(1):11-9.

PMID:
11254111
42.

Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin.

Viktorsson K, Heiden T, Molin M, Akusjärvi G, Linder S, Shoshan MC.

Apoptosis. 2000 Oct;5(4):355-67.

PMID:
11227217
43.

[The 1954 health survey of Stockholm. I. Planning & scope].

FRISK AR, HOLMGREN A, STROM G, WERKO L, WESTMAN C, VIKTORSSON KE.

Nord Med. 1957 Sep 26;58(39):1437-40; discussion 1459-62. Swedish. No abstract available.

PMID:
13484037

Supplemental Content

Loading ...
Support Center